Gold prices hit 4-month high on Fed easing hopes, tariff uncertainty
NEW YORK -On Wednesday, AngioDynamics Inc. (NASDAQ:ANGO), the medical device maker, reported better-than-expected fiscal third quarter results and raised its full-year outlook.
The company’s shares were up 10.46% in premarket trading following the results.
The Latham, New York-based company posted adjusted earnings of $0.03 per share for the quarter ended February 28, beating analyst estimates of a $0.11 per share loss. Revenue came in at $72 million, topping expectations of $70.57 million.
AngioDynamics said its MedTech segment, which includes its Auryon atherectomy platform and thrombus management products, saw sales jump 22.2% year-over-year to $31.3 million.
"We are very pleased with our third quarter performance as we continued to drive strong topline growth and adjusted EBITDA profitability," said CEO Jim Clemmer.
For fiscal 2025, the company now expects revenue between $285 million to $288 million, up from its prior forecast of $282 million to $288 million. It also raised its adjusted earnings outlook to a loss of $0.31 to $0.34 per share, compared to previous guidance for a loss of $0.34 to $0.38 per share.
The improved outlook reflects "the quality of performance we have seen through fiscal 2025," Clemmer noted.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.